As of mid-July, more than 14.3 million people worldwide have been infected with SARS-CoV, the virus that causes COVID-19. Of those, more than 602,750 have died. In the US, cases have reached over 3.7 million with over 142,000 deaths.
The COVID-19 pandemic continues to be a major factor in the financial markets as it impacts the economy, strains health care systems and government budgets.
Stocks will see more turmoil in the second half of 2020 as vaccine developments – positive and negative – continue to impact the markets on a daily basis.
The white paper examines the opportunities and challenges created by the COVID-19 pandemic on two sectors – Environmental, Social and Governance (ESG) and health care/biotech.
White paper provides snapshot view of what specific companies are doing in molecular diagnostic testing, antibody testing, therapeutics and vaccines. Tables include company stocks, return YTD, 52-week highs.
55 pages including tables, graphs and footnotes.
Table of Contents
Environmental, Social and Governance
S and G increase in importance
Innovations creating specific investment opportunities
More managers launch ESG funds
Molecular Diagnostic Tests
Stock prices in the health care sector
Listing of stocks in the CNBC COVID-19 Index Tracker
BIO’s listing of vaccine stocks
About Peltz International